REGIS NU641 CLINICAL ADV
PHARMACOLOGY FINAL EXAM
QUESTIONS WITH COMPLETE
ANSWERS
Clonodine cc- ccAnswer ccHas ccseveral ccoff-label ccuses ccincluding: ccalcohol ccand
ccnicotine ccwithdrawal ccand ccpost cctherpautic ccneuralgia
Guanfacine cc- ccAnswer cchypertension ccdrug ccthat cchas ccalso ccbeen ccapproved ccto
ccuse ccfor ccADHD
Ramelteon cc(Rozerem) cc- ccAnswer ccInsomnia ccmed ccthat ccdoes ccnot cchave ccinverse
ccrisk ccfor ccpatients ccengaging ccin ccactivities ccwhile ccsomnolent ccwith ccno ccmemory
ccof cchaving cctaking ccpill
Common ccmistakes ccpractitioners ccmake ccin cctreating ccanxiety ccdisorders cc- ccAnswer
ccGeneral ccdiagnosis ccand ccfollowing ccup ccto ccsee ccif cctreatment ccgoals ccare ccbeing
ccmet
Xanax cc- ccAnswer ccThe ccbenzodiazepine ccwith ccthe ccgreatest cclikelihood ccof
cccausing ccdependency ccs/t ccit cchas cca ccshort cchalf-life
Although cca ccpatient ccsees cca ccneurologist ccfor ccthe ccmanagement ccof ccher ccpartial
ccseizures, ccwhy ccis ccit ccimportant ccto ccknow ccher ccmedication ccregimen? cc- ccAnswer
ccThere ccare ccmany ccdrug-drug ccinteractions ccwith ccanticonvulsants
Routine cceducation ccfor ccpatient ccbeing cctreated ccwith cclevetiracetam cc(Keppra) ccfor
ccseizures cc- ccAnswer ccTo ccnot ccabruptly ccdiscontinue ccKeppra ccdue ccto ccrisk ccfor
ccwithdrawal ccseizures
What ccadvice ccyou ccwould ccgive cca ccwoman ccwho cchas ccbeen ccon ccDepakote ccfor
ccseizure ccand ccwants ccto ccget ccpregnant cc- ccAnswer ccValproate ccis cca ccknown
ccteratogen ccbut ccmay ccbe cctaken ccafter ccthe ccfirst cctrimester ccif ccnecessary
Prior ccto ccstarting ccantidepressants, ccthe ccpatient ccshould cchave cclab cctesting ccto
ccrule ccout cc- ccAnswer cchypothyroidism
, Cholinergic ccblockers ccare ccused ccto: cc- ccAnswer ccCounteract ccthe ccERS cceffects ccof
ccphenothiazines
Control cctremors ccand ccrelax ccsmooth ccmuscles ccin ccParkinson's ccDisease
Inhibit ccthe ccmuscarinic ccaction ccof ccAch ccon ccbladder ccmuscle
Memantine cc- ccAnswer ccA ccdrug ccused ccto cctreat ccAlzheimer's ccdisease ccbut ccis ccnot
ccan ccanticholinergic
Verapamil cc- ccAnswer ccPreventative cctherapy ccfor cccluster ccheadache
Minocycline cc(PO) cc- ccAnswer cc
When ccprescribing ccfor ccmigraines, ccpatient cceducation ccincludes: cc- ccAnswer ccStress
ccreduction ccand ccregular ccsleep ccare ccintegral ccto ccmigraine cctreatment
Acetaminophen cc- ccAnswer ccMigraines ccin ccpregnancy ccmay ccbe ccsafely cctreated
ccwith ccthis
When ccare ccmigraines ccconsidered cccured? cc- ccAnswer ccThere ccis ccno ccknown cccure
Nonpharmacologic ccTherapy ccfor cctension ccheadache ccincludes: cc- ccAnswer
ccbiofeedback, ccstress ccmanagement, ccmassage cctherapy
Fluoxetine cc- ccAnswer ccFirst-line ccantidepressant ccfor ccchildren ccwith ccmajor
ccdepression ccbetween cc8 ccto cc17 ccyears ccold
SSRIs cc- ccAnswer ccContains cca ccblack-box ccwarning ccof ccsuicidal ccideation ccin
ccpediatric ccand ccadolescent ccgroups
Stimulants cc(methylphenidate ccor ccamphetamine ccsalts) cc- ccAnswer ccAre ccthe ccmost
cceffective cctherapy ccand ccare ccgenerally ccfirst ccline ccof cctreatment ccof ccADHD ccin
ccchildren ccunless cccontraindications ccexist
Hypercalcemia cc- ccAnswer ccPt cctreated ccwith ccmore ccthan cc100 ccgrams ccper ccweek
ccof cctopical cccalcipotriene ccfor ccpsoriasis ccneed ccto ccbe ccmonitored ccfor
An ccadolescent ccfemale cccalls ccthe ccclinic ccwith ccconcerns ccthat ccher ccacne ccis
ccworse cc2 ccweeks ccafter ccstarting cctopical cctretinoin. ccWhat ccwould ccbe ccthe
ccappropriate cccare ccfor ccher? cc- ccAnswer ccReassure ccher ccthat ccthe ccworsening ccof
ccacne ccis ccnormal ccand ccit ccshould ccimprove ccwith cccontinued ccuse
Treatment ccfor ccTinea cccapitis cc- ccAnswer ccOral ccgriseofulvin ccor ccBiweekly
ccshampoo ccwith ccselenium ccsulfide ccor ccketoconazole ccfor cc6 ccto cc8 ccweeks
PHARMACOLOGY FINAL EXAM
QUESTIONS WITH COMPLETE
ANSWERS
Clonodine cc- ccAnswer ccHas ccseveral ccoff-label ccuses ccincluding: ccalcohol ccand
ccnicotine ccwithdrawal ccand ccpost cctherpautic ccneuralgia
Guanfacine cc- ccAnswer cchypertension ccdrug ccthat cchas ccalso ccbeen ccapproved ccto
ccuse ccfor ccADHD
Ramelteon cc(Rozerem) cc- ccAnswer ccInsomnia ccmed ccthat ccdoes ccnot cchave ccinverse
ccrisk ccfor ccpatients ccengaging ccin ccactivities ccwhile ccsomnolent ccwith ccno ccmemory
ccof cchaving cctaking ccpill
Common ccmistakes ccpractitioners ccmake ccin cctreating ccanxiety ccdisorders cc- ccAnswer
ccGeneral ccdiagnosis ccand ccfollowing ccup ccto ccsee ccif cctreatment ccgoals ccare ccbeing
ccmet
Xanax cc- ccAnswer ccThe ccbenzodiazepine ccwith ccthe ccgreatest cclikelihood ccof
cccausing ccdependency ccs/t ccit cchas cca ccshort cchalf-life
Although cca ccpatient ccsees cca ccneurologist ccfor ccthe ccmanagement ccof ccher ccpartial
ccseizures, ccwhy ccis ccit ccimportant ccto ccknow ccher ccmedication ccregimen? cc- ccAnswer
ccThere ccare ccmany ccdrug-drug ccinteractions ccwith ccanticonvulsants
Routine cceducation ccfor ccpatient ccbeing cctreated ccwith cclevetiracetam cc(Keppra) ccfor
ccseizures cc- ccAnswer ccTo ccnot ccabruptly ccdiscontinue ccKeppra ccdue ccto ccrisk ccfor
ccwithdrawal ccseizures
What ccadvice ccyou ccwould ccgive cca ccwoman ccwho cchas ccbeen ccon ccDepakote ccfor
ccseizure ccand ccwants ccto ccget ccpregnant cc- ccAnswer ccValproate ccis cca ccknown
ccteratogen ccbut ccmay ccbe cctaken ccafter ccthe ccfirst cctrimester ccif ccnecessary
Prior ccto ccstarting ccantidepressants, ccthe ccpatient ccshould cchave cclab cctesting ccto
ccrule ccout cc- ccAnswer cchypothyroidism
, Cholinergic ccblockers ccare ccused ccto: cc- ccAnswer ccCounteract ccthe ccERS cceffects ccof
ccphenothiazines
Control cctremors ccand ccrelax ccsmooth ccmuscles ccin ccParkinson's ccDisease
Inhibit ccthe ccmuscarinic ccaction ccof ccAch ccon ccbladder ccmuscle
Memantine cc- ccAnswer ccA ccdrug ccused ccto cctreat ccAlzheimer's ccdisease ccbut ccis ccnot
ccan ccanticholinergic
Verapamil cc- ccAnswer ccPreventative cctherapy ccfor cccluster ccheadache
Minocycline cc(PO) cc- ccAnswer cc
When ccprescribing ccfor ccmigraines, ccpatient cceducation ccincludes: cc- ccAnswer ccStress
ccreduction ccand ccregular ccsleep ccare ccintegral ccto ccmigraine cctreatment
Acetaminophen cc- ccAnswer ccMigraines ccin ccpregnancy ccmay ccbe ccsafely cctreated
ccwith ccthis
When ccare ccmigraines ccconsidered cccured? cc- ccAnswer ccThere ccis ccno ccknown cccure
Nonpharmacologic ccTherapy ccfor cctension ccheadache ccincludes: cc- ccAnswer
ccbiofeedback, ccstress ccmanagement, ccmassage cctherapy
Fluoxetine cc- ccAnswer ccFirst-line ccantidepressant ccfor ccchildren ccwith ccmajor
ccdepression ccbetween cc8 ccto cc17 ccyears ccold
SSRIs cc- ccAnswer ccContains cca ccblack-box ccwarning ccof ccsuicidal ccideation ccin
ccpediatric ccand ccadolescent ccgroups
Stimulants cc(methylphenidate ccor ccamphetamine ccsalts) cc- ccAnswer ccAre ccthe ccmost
cceffective cctherapy ccand ccare ccgenerally ccfirst ccline ccof cctreatment ccof ccADHD ccin
ccchildren ccunless cccontraindications ccexist
Hypercalcemia cc- ccAnswer ccPt cctreated ccwith ccmore ccthan cc100 ccgrams ccper ccweek
ccof cctopical cccalcipotriene ccfor ccpsoriasis ccneed ccto ccbe ccmonitored ccfor
An ccadolescent ccfemale cccalls ccthe ccclinic ccwith ccconcerns ccthat ccher ccacne ccis
ccworse cc2 ccweeks ccafter ccstarting cctopical cctretinoin. ccWhat ccwould ccbe ccthe
ccappropriate cccare ccfor ccher? cc- ccAnswer ccReassure ccher ccthat ccthe ccworsening ccof
ccacne ccis ccnormal ccand ccit ccshould ccimprove ccwith cccontinued ccuse
Treatment ccfor ccTinea cccapitis cc- ccAnswer ccOral ccgriseofulvin ccor ccBiweekly
ccshampoo ccwith ccselenium ccsulfide ccor ccketoconazole ccfor cc6 ccto cc8 ccweeks
